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H U M A N  G E N E T I C S
Functional validity, role, and implications of heavy 
alcohol consumption genetic loci
Andrew Thompson1,2,3*, James Cook4, Hélène Choquet5, Eric Jorgenson5, Jie Yin5, 
Tarja Kinnunen6, Jeff Barclay7, Andrew P. Morris4, Munir Pirmohamed1,2,3
High alcohol consumption is a risk factor for morbidity and mortality, yet few genetic loci have been robustly 
associated with alcohol intake. Here, we use U.K. Biobank (n = 125,249) and GERA (n = 47,967) datasets to determine 
genetic factors associated with extreme population-level alcohol consumption and examine the functional validity 
of outcomes using model organisms and in silico techniques. We identified six loci attaining genome-wide significant 
association with alcohol consumption after meta-analysis and meeting our criteria for replication: ADH1B (lead 
SNP: rs1229984), KLB (rs13130794), BTF3P13 (rs144198753), GCKR (rs1260326), SLC39A8 (rs13107325), and DRD2 
(rs11214609). A conserved role in phenotypic responses to alcohol was observed for all genetic targets available 
for investigation (ADH1B, GCKR, SLC39A8, and KLB) in Caenorhabditis elegans. Evidence of causal links to lung cancer, 
and shared genetic architecture with gout and hypertension was also found. These findings offer insight into genes, 
pathways, and relationships for disease risk associated with high alcohol consumption.
INTRODUCTION
Alcohol consumption is associated with over 60 diseases, with the 
risk of these comorbidities generally increasing with greater exposure 
(1). Excessive consumption of alcohol is considered a result of complex 
interactions between genetic and nongenetic risk factors. Nongenetic 
factors associated with levels of alcohol intake include gender (2), 
age at first alcohol use (3), duration of poverty and involuntary 
unemployment (4), and other lifestyle risk factors (5).
Meta-analysis from twin and adoption studies has shown that 
half of the variance for alcohol use disorder (AUD) is explained by 
genetic factors (6). The discovery of well-replicated risk loci, how-
ever, has been limited to the alcohol metabolizing genes alcohol 
dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). 
Missense variants, rs1229984 (G-->A; p.Arg48His) in ADH1B and 
rs671 (G-->A; p.Glu504Lys) in ALDH2, are protective against higher 
alcohol consumption and alcohol misuse phenotypes (7). For ex-
ample, in a meta-analysis of ~3800 European ancestry individuals, 
the ADH1B rs1229984 variant was strongly associated with reduced 
risk of alcohol dependence and lower number of maximum drinks 
in 24 hours (8). The ADH1B and other ADH and ALDH variants 
that are associated with alcohol consumption occur at low frequency 
among European ancestry populations but are more common in East 
Asian ancestry populations, where the standardized population 
prevalence of alcohol misuse is lower (9).
Larger samples and genome-wide screens have been used to 
identify previously unidentified loci beyond the ADH-ADLH cluster. 
Alcohol consumption phenotypes are of specific interest to the field 
as they are often more applicable to the wider population than the 
AUD criteria. Through genome-wide association studies (GWAS), 
single-nucleotide polymorphisms (SNPs) mapping to/near KLB, AUTS2, 
SERPINC1, ANKRD36, GCKR, PXDN, CADM2, HGFAC, SLC39A8, and 
TNFRSF11A have been associated with alcohol consumption in European 
ancestry populations at genome-wide significance (P < 5 × 10−8) (10–15). 
However, apart from association signals at KLB and GCKR, strong 
evidence of replication has been limited.
In this study, our aim was to determine factors associated with 
heavy alcohol consumption in white British individuals from the 
U.K. Biobank (UKB) (www.ukbiobank.ac.uk/), alongside exploring 
the functional relevance of genome-wide significant variants using 
model organisms and data mining techniques.
RESULTS
Nongenetic factors
The application of the phenotype definition resulted in the identifica-
tion of 21,967 cases and 103,282 controls that had complete data for 
all covariates. The covariates included in the final logistic regression 
model and carried forward to the GWAS analysis were (table S1) age 
at recruitment, sex, smoking status (anytime versus never), property 
ownership (own versus rent), body mass index (BMI), Townsend 
deprivation index at recruitment, adopted as a child, and long- 
standing illness, disability, or infirmity (yes or no).
High alcohol consumption loci
We tested for SNP-level association with our high alcohol con-
sumption phenotype in UKB. A total of 11,141,077 SNPs survived 
central quality control (QC) by UKB and post-GWAS filtering for 
imputation quality and minor allele frequency. The GWAS data test 
statistics showed modest deviation from the null (GC = 1.09; Fig. 1, 
inset), although linkage disequilibrium (LD) score regression 
intercept = 1.02 suggests most of the inflation is consistent with 
polygenic architecture. We then carried forward lead SNPs at 
P < 5 × 10−6 from UKB to Genetic Epidemiology Research in Adult 
Health and Aging (GERA) for replication. We report validated 
associations that meet genome-wide significance in the meta-analysis 
of UKB and GERA, which also demonstrate nominal association 
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with the same direction of effect in GERA (Table 1). A summary of 
all SNPs reaching P < 5 × 10−8 in UKB can be found in table S2. We 
identified six loci attaining genome-wide significant association 
with alcohol consumption after meta-analysis and meeting our 
criteria for replication: ADH1B (rs1229984; P_meta = 2.3 × 10−66); 
KLB (rs13130794; P_meta = 5.7 × 10−16); BTF3P13 (rs144198753; 
P_meta = 4.1 × 10−29); GCKR (rs1260326; P_meta = 1.5 × 10−13); 
SLC39A8 (rs13107325; P_meta = 6.7 × 10−9); and DRD2 (rs11214609; 
P_meta = 4.3 × 10−9) (Table 1).
 Multiple distinct signals of association observed at alcohol 
consumption loci
Conditional analyses revealed an additional signal (P < 1 × 10−5) 
(Table 2) at the SLC39A8 locus (NFKB1). Given ADH1B and BTF3P13 
are located <1 Mb apart on q23 of chromosome 4, we conducted a 
wider conditional analysis across a 1.5-Mb region, which included 
both SNPs. The analysis identified eight independent SNPs mapping 
to/near ADH1A, ADH1B, ADH4, ADH5, TSPAN5, and EIF4E. The 
signal mapping to BTF3P13 did not meet locus-wide significance in 
conditional analysis, suggesting a false positive for this variant.
 Previously reported loci
The signals described in this section meet our validated association 
criteria and have been reported for various alcohol phenotypes by 
other groups. The lead SNP at ADH1B, rs1229984 [risk allele frequency 
(RAF), 0.980; P = 3.3 × 10−36; fig. S1A], is the missense variant 
(G-->A; p.His48Arg) that has been widely replicated. The lead SNP 
rs13130794 (RAF, 0.632; P = 4.0 × 10−9; fig. S1B) is located in the 
KLB locus and has been reported to be associated with alcohol 
intake in the UKB (11) and a separate European cohort of >98,000 
individuals (10). The lead variant in chromosome 2, rs1260326 
(RAF, 0.612; P = 2.6 × 10−8; fig. S1C), is in GCKR, a glucokinase 
regulatory gene. This specific SNP has been reported as genome- 
wide significant for alcohol consumption (i.e., drinks/week) in large- 
scale European ancestry (11, 13) and transethnic populations (15). 
The lead SNP rs13107325 (RAF, 0.928; P = 1.6 × 10−8; fig. S1D) is 
in the zinc transporter gene, SLC39A8, which has been linked in 
Europeans to AUD Identification Test (AUDIT) (14) and AUDIT-C 
outcomes, and to AUD diagnosis (15). Last, rs11214609 (RAF, 
0.395; P = 4.3 × 10−9; fig. S1E) was the SNP in the DRD2 locus. 
DRD2 often has been cited in addiction phenotypes and has been 
identified for AUD, but not alcohol consumption (15).
Nonreplicated signals reported elsewhere
We also observed genome-wide significant evidence of association 
in UKB at FTO and CRHR1, but these signals could not be validated 
in GERA. There is, however, evidence for association with alcohol- 
related phenotypes at these loci from other studies. The lead SNP 
rs55872725 (RAF, 0.599; P = 2.6 × 10−8) is in the FTO gene. This 
locus has recently been reported to be associated with AUDIT-C 
and AUD diagnosis in European ancestry individuals (15). Different 
index variants were reported between studies, rs62033408 for 
AUDIT-C and AUD diagnosis outcomes, but the SNPs are in strong 
LD with each other (r2 = 0.92). The FTO locus has been strongly 
associated with BMI, obesity, and, subsequently, type 2 diabetes as a 
clinical end point. Our lead SNP in this locus is in complete LD 
(r2 = 1.0) with rs1558902 in Europeans, which is the lead SNP for 
BMI in the largest published GWAS to date (16). The CRHR1 locus, 
with rs1635291 (RAF, 0.754; P = 4.5 × 10−10) as the lead SNP, has 
been identified through gene-based analysis in a previous alcohol 
consumption GWAS where never drinkers were excluded. However, 
no other groups have reported this locus directly through GWAS. 
Fig. 1. Manhattan plot of the GWAS outcomes for alcohol consumption phenotype using the entire UKB cohort (n = 125,249). Inset: QQ plot of expected versus 
observed GWAS results from UKB, demonstrating modest deviation from the null, GC = 1.09.
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Given the previous associations for these loci with covariates in-
cluded in our analysis but not in the GERA dataset, we explored the 
potential for collider bias at rs55872725 when not adjusting for 
BMI, and rs1635291 when not adjusting for smoking; the results 
were consistent at 6.5 × 10−6 and 2.8 × 10−8, respectively. We also 
found our lead SNP in the CRHR1 locus to be in strong LD (r2 = 0.87) 
with a tag SNP rs1800547 for a common inversion polymorphism 
in 17q21.31 (17).
In silico analysis
Of the six validated variants from the UKB and GERA cohorts, 
three were identified as expression quantitative trait loci (eQTLs) 
through the Genotype-Tissue Expression (GTEx) database (table S3). 
rs11214609 showed evidence of being an eQTL in various tissues 
for nearby genes, ANNK1 and TTC12. rs13130794 was associated 
with the expression of RFC1 in the cerebellar hemisphere and skeletal 
muscle and UDGH in blood. rs1260326 was a broader eQTL with 
evidence across eight loci and various tissues including skeletal muscle, 
thyroid, and adrenal glands. Table S4 describes the LD between the 
top eQTL SNP for any eQTL signal and the GWAS SNP. None of 
the SNP pairs demonstrated evidence of colocalization based on a 
threshold of LD r2 > 0.8.
The validated SNPs were submitted to Gene ATLAS to explore 
phenome-wide association study (PheWAS) outcomes in disease 
phenotypes via International Statistical Classification of Diseases, 10th 
Revision (ICD-10) codes. Evidence suggests that these SNPs contribute 
to a range of diseases including alcohol dependence, hypertension, 
skeletal disorders, gout, alcoholic liver disease, ischemic heart 
diseases, metabolic disorder, obesity, and diabetes mellitus (table S5). 
The ADH1B variant is associated with lipid metabolism disorder, giving 
further link between alcohol intake and liver fat accumulation.
A set of 37 loci, which reached 5 × 10−6 with heavy drinker status 
phenotype in UKB, were submitted to the Reactome Knowledgebase 
for pathway analysis (table S6). Six pathways across three distinct 
processes were found to be significant. The most prominent out-
come related to signaling of phosphatidylinositol 3-kinase (PI3K) 
and PI3K/AKT pathways, particularly in reference to cancer. Dys-
function of the PI3K/AKT pathway is widely implicated in many 
cancers and is a key regulator of cell survival through downstream 
targets (18). The genes implicated in these pathways were KLB 
and ESR1 (fig. S2). The other two pathways were neurexins and 
neuroligins, driven by LRRTM4 and NRXN3, and TFAP2 (AP-2) 
family regulation of transcription of growth factors and their recep-
tors, driven by ESR1.
Through genetic correlation analysis of the entire genome, we 
identified 21 significant correlations that survived multiple testing 
correction. These outcomes are summarized in Fig. 2. The traits 
with the strongest correlations included smoking variables [e.g., 
ever versus never smoked (rg = 0.48, PFDR = 2.60 × 10−13) and age 
of smoking initiation (rg = −0.41, PFDR = 0.006)], several lung can-
cer outcomes [e.g., squamous cell lung cancer (rg = 0.37, PFDR = 0.006) 
and lung cancer (rg = 0.36, PFDR = 1.20 × 10−4)], and mothers age at 
death (rg = −0.41, PFDR = 1.60 × 10−4). Several education measures 
and mental health conditions were also found to have significant 
correlations.
Mendelian randomization (MR) was used to examine the causal 
relationship between our heavy drinker case-control phenotype and 
111 selected traits and clinical outcomes. The number of SNPs used 
for instrumental variables for each outcome test varied between two 
and six. Twelve outcomes including four insulin-related and two 
lung cancer outcomes demonstrated nominal significance using the 
inverse variance–weighted (IVW) method, although only evidence 
of a protective effect for ischemic stroke survived multiple testing 
correction (table S7). The MR-Egger regression intercept demon-
strated no evidence of horizontal pleiotropy for the 12 outcomes 
(P ≥ 0.11). Single SNP analysis revealed that rs1229984 was not 
included in the instrumental variable for ischemic heart disease 
(SNP or appropriate proxy not available in the outcome dataset). 
Given rs1229984 demonstrates a consistent and large effect size 
across genetic studies of alcohol-related phenotypes, it is question-
able whether the outcome can be considered as truly representative 
for this disease.
Table 1. Summary of validated associations that meet genome-wide significance in the meta-analysis of UKB and GERA, which also demonstrate 
nominal association with the same direction of effect in GERA. OR, odds ratio; CI, confidence interval. 






Chr Position Lead SNP Locus Risk allele Other allele RAF OR(95% CI) P  (SE) P P
2 27730940 rs1260326 GCKR C T 0.612 1.06(1.04–1.08) 2.6 × 10
−8 0.033 
(0.029) 1.1 × 10
−6 1.5 × 10−13
4 39422242 rs13130794 KLB T C 0.632 1.07(1.05–1.09) 2.6 × 10
−10 0.035 
(0.007) 4.2 × 10
−7 5.7 × 10−16
4 99713350 rs144198753 BTF3P13 C T 0.991 1.66(1.48–1.85) 2.70 × 10
−18 0.156 
(0.023) 2.1 × 10
−11 4.1 × 10−29
4 100239319 rs1229984 ADH1B C T 0.980 1.58(1.48–1.70) 3.30 × 10
−36 0.187 
(0.016) 2.9 × 10
−32 2.3 × 10−66
4 103188709 rs13107325 SLC39A8 C T 0.928 1.12(1.08–1.16) 1.60 × 10
−8 0.029 
(0.013) 0.0249 6.7 × 10
−9
11 113316102 rs11214609 DRD2 G C 0.395 1.06(1.04–1.08) 2.10 × 10
−7 0.021 
(0.007) 0.0035 4.30 × 10
−9
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To further explore the potential causal effect of heavy alcohol 
consumption on lung cancer outcomes and allow for potential 
pleiotropy that might be driven by smoking, we repeated our GWAS 
analysis stratified for smoking status (ever versus never) and per-
formed MR to assess potential collider bias. The SNPs used as the 
instrumental variable in the original analysis were retained, and 
lung adenocarcinoma and lung cancer were the only outcomes 
investigated. Evidence of consistent outcomes was observed in both 
stratified groups using IVW, although lung cancer in never smokers 
was the only outcome that did not reach the statistical significance 
threshold (P = 0.085).
Functional effects in model organisms
To verify whether validated genetic targets (i.e., ADH1B, GCKR, 
SLC39A8, and KLB) had a conserved role in phenotypic responses 
to alcohol, we investigated the acute effects of ethanol on the nem-
atode worm, Caenorhabditis elegans. In comparison to wild-type 
animals, those with a loss-of-function mutation in the worm or-
tholog for ADH (sodh-1 in C .elegans) had a statistically enhanced 
ethanol response (Fig. 3) as has been previously described in detail 
(19). The effect of intoxicating ethanol on coordinated locomotion 
was next quantified for loss-of-function mutations in C. elegans 
glucokinase (GK; hxk-1) and solute carrier family 39 member 8 
(SLC39A8; zipt-15) (Fig. 3). Without an ortholog for GCKR in 
C. elegans, we instead analyzed its downstream effector protein 
glucokinase itself. Loss-of-function mutations in these genes sig-
nificantly reduced the effect of ethanol for GK and SLC39A8 (Fig. 3), 
underlining a conserved role for these genes in whole-animal re-
sponses to alcohol. We also quantified single mutations in the 
C. elegans orthologs for the β-Klotho protein (KLB; klo-1 and klo-2) 
and found that individual mutations did not alter the ethanol 
phenotype (fig. S3A). A compound mutation of both klo-1 and 
klo-2 (20), however, did have a significantly enhanced ethanol effect 
(Fig. 3).
To validate the effects seen in individual mutant strains, we 
performed RNA interference (RNAi) experiments to knock down 
expression of the contraindicated genes. In comparison to control, 
RNAi knockdown of GK (hxk-1) and SLC39A8 (zipt-15) resulted 
in the same phenotypic effects as did the mutations (Fig. 4). In our 
RNAi experiments, knockdown of ADH (sodh-1) did not result 
in a significant decrease. Similar to the KLB mutations, individual 
knockdown of C. elegans KLB (klo-1 or klo-2) did not statistically 
enhance the ethanol phenotype and neither did knocking down 
both klo-1 and klo-2 simultaneously (Fig. 4). The lack of effect in the 
double knockdown is perhaps expected given that RNAi efficiency 
can be reduced with multiple targets (21). To validate the alcohol 
effect of KLB in C. elegans in an alternative method, we performed 
RNAi on individual KLB genes in the mutant strain of the other 
ortholog (i.e., klo-1 RNAi in the klo-2 background; klo-2 RNAi in 
the klo-1 background). In both cases, there were exceptionally en-
hanced effects of ethanol similar to that seen with the compound 
mutant strain (fig. S3B).
DISCUSSION
We report here a large alcohol consumption GWAS, including 
125,249 white British participants, with subsequent replication and 
meta-analysis in an additional 47,967 individuals. Moreover, and as 
promoted by Salvatore and colleagues in this field (22), we conducted 
a post-GWAS study to investigate the biological implications of our 
findings. This includes providing evidence of a conserved role in 
phenotypic responses to alcohol for all targets available for investi-
gation (ADH1B, GCKR, SLC39A8, and KLB) in C. elegans.
The primary strengths of this study are the (i) large sample size; 
(ii) replication and subsequent meta-analysis; (iii) post-GWAS 
analysis, including functional assessment using C. elegans; and 
(iv) use of a mixed-model approach in GWAS to account for relatedness. 
There are, however, several limitations that require discussion. 
First, the alcohol data and, therefore, the case-control phenotypes 
are based on self-reported alcohol intake. It is well documented that 
individuals underreport their alcohol consumption for a number of 
reasons. This presents risk of cases being mislabeled as controls, 
alongside the granularity of the data being reduced by the categorical 
approach. There are also differences in the measurement scale 
between discovery and replication cohorts. This difference was 
handled by applying a z score approach to meta-analysis. Second, 
Table 2. Summary of conditional analysis using outcomes from UKB. Joint models refer to the estimated joint effects of all selected SNPs in a region (i.e., all 








frequency  SE P Joint  Joint SE Joint P
rs13107325 4 rs13107325 SLC39A8 103188709 C 0.928 0.111 0.020 1.6 × 10−8 0.112 0.020 1.4 × 10−8
rs13107325 4 rs13116422 NFKB1 103387160 T 0.916 0.091 0.019 1.9 × 10−6 0.092 0.019 1.7 × 10−6
Extended analysis of 4.q23 region containing ADH1B (rs1229984) and BTF3P13 loci (rs144198753)
4 rs1229984 ADH1B 100239319 T 0.020 −0.455 0.036 3.3 × 10−36 −0.467 0.036 8.7 × 10−38
4 rs551676206 ADH5 100019089 A 0.990 0.514 0.053 6.2 × 10−22 0.528 0.054 6.1 × 10−23
4 rs62307263 ADH1A 100167112 C 0.899 0.083 0.017 1.1 × 10−6 0.169 0.023 1.9 × 10−13
4 rs140859990 TSPAN5 99456373 G 0.937 −0.102 0.021 2.0 × 10−6 −0.102 0.021 1.9 × 10−6
4 rs182381822 ADH4 100179872 T 0.993 −0.274 0.069 7.2 × 10−5 −0.344 0.069 7.1 × 10−7
4 rs1800761 ADH4 100065593 T 0.183 −0.046 0.013 0.00054 −0.401 0.034 5.3 × 10−33
4 rs200411287 ADH4 100078163 A 0.851 −0.023 0.015 0.12 −0.520 0.038 4.4 × 10−42
4 rs150187763 EIF4E 99801016 A 0.982 0.010 0.039 0.79 −0.313 0.047 2.8 × 10−11
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we restricted analysis to those of white British ancestry to limit popu-
lation structure variability on outcomes. This restricts generalizability 
outside of European populations. Third, we recognize limitations to 
our MR approach: (i) MR is considered most powerful when instru-
mental variables are from a continuous trait. This is of greater concern, 
however, when a disease-specific phenotype is used for instrument 
selection because of the likely contribution of various factors in 
disease pathology; and (ii) an inherent assumption of MR is that 
variants show no pleiotropy or direct effects on the outcome. This 
requires knowledge of the underlying biology under investigation, 
although this is rarely complete. Last, we were unable to undertake 
functional assessment of all genome-wide significant loci due to there 
being either no specific C. elegans orthologs, or too many nonspecific 
orthologs, or fatal consequences of gene knockdown.
The largest and most robust effects were observed in ADH1B, 
including replicated findings from the work in C. elegans for ADH 
(19), providing confidence for the selected phenotype. The biological 
validity of polymorphisms in ADH loci is well documented and 
discussed in detail in other GWAS publications (12).
KLB has been previously associated with alcohol phenotypes in 
European populations (10, 12). A biological basis for KLB has been 
proposed in mice, where those lacking -Klotho had increased alcohol 
consumption (10). This behavior was refractory to recombinant 
fibroblast growth factor 21 (FGF21), a hormone involved in sugar 
intake regulation and for which -Klotho is an obligate coreceptor. 
Hence, down-regulation of KLB may lead to sustained intake of 
alcohol and/or high-sugar food. Moreover, loss of both KLB isoforms 
in C. elegans caused an enhancement in the ethanol effects. Further 
evidence for energy processing pathways being implicated in alcohol 
consumption is demonstrated by the genome-wide significant out-
comes for GCKR and SLC39A8, with these findings being consistent 
with recent publications (11, 13, 14). The data from our functional 
work in hexokinase and ZRT/IRT-like protein transporter supports 
Fig. 3. Genetic targets identified by GWAS have conserved roles in alcohol 
phenotypes. C. elegans with loss-of-function mutations in worm orthologs to ADH 
(sodh-1), glucokinase (hxk-1), solute carrier family 39 member 8 (zipt-15), and 
β-Klotho protein (klo-2;klo-1) were exposed to ethanol, and the resultant effect on 
locomotion rate was determined. Results are presented normalized to locomotion 
of untreated worms [basal locomotion rate: 99.03 ± 1.47 (Bristol N2 controls), 
103.13 ± 3.66 (sodh-1), 87.37 ± 1.91 (hxk-1), 31.43 ± 2.97 (zipt-15), and 99.90 ± 21.7 
(klo-2;klo-1)]. *P < 0.05.
Fig. 2. Genetic correlation between alcohol phenotype and other traits using LD score regression from LDHub. 
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the role of glucose metabolism pathways in the susceptibility to 
heavy alcohol consumption by demonstrating attenuation of the 
depressive effects of high-dose alcohol when hxk-1 and zipt-15 are 
independently knocked down. Although we failed to demonstrate 
replication between the UKB and GERA cohorts, potentially due to 
variation in phenotype, evidence from other GWAS showed consistent 
effects for FTO (23). The suggestive association with this pleiotropic 
locus adds further plausibility of common pathways implicated in 
the consumption of food and alcohol. The purported shared patho-
genic architecture may result in dysregulation of brain reward path-
ways leading to excess consumption (24). Controlling for BMI within 
our GWAS suggests that the associations for alcohol consumption 
are independent of BMI, adding weight to the hypothesis of a 
potentially shared, rather than mediated, pathways.
DRD2 encodes the dopamine receptor 2 subtype and is linked to 
several neurobiological processes, including functional activation 
of reward circuits (25). Data from in vivo and in vitro experiments 
show DRD2 to be a susceptibility gene for alcohol dependence (26), 
and altering DRD2 expression leads to differential responses to sub-
stances and stimuli (27), conferring increased risk for addiction. 
Moreover, evidence suggests increased risk of relapse in alcohol and 
cocaine dependence, and heightened heroin, nicotine, and glucose 
craving when polymorphisms of DRD2 are present or there is low 
D2 receptor availability (28). The association of DRD2 with alcohol 
was confirmed in GWAS findings for AUD but not alcohol con-
sumption, with authors proposing that the central nervous system is 
a fundamental element in the progression to clinical diagnosis (15). 
Our findings are somewhat contradictory given that participant catego-
rization is based on U.K. alcohol units consumed per week, although 
the quantities for cases are often associated with high risk of AUD.
Together, the loci outside of the ADH/ALDH cluster suggest 
several common pathways associated with different types of com-
pulsive behavior and addiction phenotypes. Considerable evidence 
from animal models and from humans supports convergence of 
these common etiologies in the brain’s limbic system regardless 
of the prior distinct mechanism of action and ultimate observable 
phenotype (29, 30). This suggests that addiction might be better 
considered as a pathobiological risk with different endotypes, rather 
than each specific phenotype (e.g., alcohol dependence, drug addic-
tion, and gambling addiction) being independently characterized. 
From a therapeutics perspective, these outcomes provide additional 
and supportive evidence toward a number of targets that might be 
amendable to pharmacological intervention. Further investigation 
is required to determine which sites have the greatest potential. 
Data from the Open Targets resource (www.opentargets.org/) 
suggest that 49 drugs have reached phase IV investigation for DRD2 
across a range of indications, including mental health disorders and 
cocaine dependence; no drugs are in development for ADH1B, KLB, 
GCKR, or SLC39A8. FGF21 has been explored due to links with KLB, 
but no drugs are in the market yet.
Using the GWAS outcomes from UKB enabled us to examine 
the relations between key variants/loci and traits and disease pheno-
types. Genetic correlation analysis and MR consistently demonstrated 
an association with lung cancer. Determining alcohol’s contribution 
to lung cancer often has been limited by the strong positive cor-
relation between alcohol intake and smoking. However, the outcomes 
from the MR provide potential evidence of a causal relationship in 
our overall sample and when stratified by smoking status. Alcohol 
is a known carcinogen and is implicated in cancers of the liver, 
colon, rectum, head and neck, and breast, for example (31), while 
evidence for lung is variable (32, 33). Lung cancer is a complex and 
multifactorial disease involving genetic and a range of measurable 
and nonmeasurable environmental and lifestyle factors. Hence, 
heavy alcohol consumption is one potentially modifiable risk factor 
to reduce disease incidence. An alternative hypothesis is through a 
joint risk locus in KLB that independently drives alcohol consump-
tion and cancer risk. In addition to the above, -Klotho inhibits 
PI3K and, subsequently, AKT, an important pathway in normal cell 
function. The dysfunction of the PI3K/AKT pathway, identified in 
our pathway analysis, has been cited in cancerous cells and as a risk 
factor in cancer onset (18, 34). Down-regulation of KLB has been 
reported across several cancers (35, 36). However, some variations 
in findings exist (37), and no evidence is available in lung cancer. 
Basic cell line study would provide initial data on -Klotho expres-
sion in lung tumor cells.
Links to other diseases were also found. Drinking heavily was 
suggested as a protective factor for ischemic stroke. This is not con-
sistent with traditional epidemiological findings or other MR find-
ings using rs1229984 as the instrumental variable (38). However, 
the lack of rs1229984 in our instrumental variable for this analysis 
means the outcome should be interpreted with caution. The nominal 
evidence in several insulin measures suggests a wider biological 
association with glucose regulation, linking back to the potential 
importance of energy metabolism pathways in alcohol consump-
tion. ADH1B and GCKR were associated with gout, and ADH1B 
alone with hypertension. The lead SNP at GCKR, rs1260326, has 
been shown to be a risk variant for gout in a separate GWAS (39), 
and rs1229984 in ADH1B has been identified for systolic blood 
pressure using a functional enrichment approach. Increasing alcohol 
consumption is a known risk factor for both gout and hypertension 
(40). Last, there was evidence for several skeletal complications with 
identified alcohol consumption variants. Alcohol intake represents a 
dose-dependent risk factor for fragility fractures due to the direct effects 
of alcohol on bone cell metabolism. Chronic alcohol consumption 
has been associated with a twofold increased risk of hip fracture in 
prospective cohort studies involving more than 16,000 subjects (41).
Fig. 4. RNAi of genetic targets. RNAi knockdown of worm orthologs to glucokinase 
(hxk-1) and solute carrier family 39 member 8 (zipt-15) phenocopies the loss-of-function 
mutations. Results are presented as locomotion of worms treated with ethanol 
normalized to untreated worms [basal locomotion rate: 87.63 ± 21.6 (empty vector 
control), 94.17 ± 2.91 (sodh-1), 77.60 ± 2.34 (hxk-1), 60.0 ± 2.34 (zipt-15), 90.97 ± 3.56 
(klo-1), 99.13 ± 2.78 (klo-2), and 110.0 ± 3.40 (klo-2;klo-1)].  *P < 0.05; n.s., not significant.
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CONCLUSION
Our findings offer insight into genes, pathways, and causal relation-
ships for disease risk associated with heavy alcohol consumption. 
The inclusion of model organism work to investigate the conserved 
role of loci alongside GWAS outcomes is novel in the alcohol field 
and adds validity for relevant outcomes. In addition, the correlation 
between the C. elegans phenotypic data with genome-wide associa-
tion in humans reinforces a link between the acute physiological 
effect of alcohol and predisposition to excessive alcohol consump-
tion. Specific findings suggesting joint reward/addiction pathways, 
the role of energy metabolism, casual links to lung cancer, and shared 
genetic architecture with gout and hypertension are of particular 
interest. Further investigation is required, however, to realize the 




UKB is a large population cohort of ~502,000 individuals from 
the United Kingdom aged 40 to 69 years at the time of recruitment. 
Baseline assessment was undertaken at one of 22 centers across the 
United Kingdom between 2006 and 2010. Each participant completed 
a comprehensive demographic, lifestyle, and health questionnaire, 
underwent clinical phenotyping, provided biological samples (i.e., 
blood, urine, and saliva), and agreed to have his or her health record 
accessed for baseline and follow-up outcomes (42). Ethical approval for 
UKB was gained from the Research Ethics Service (REC reference: 
16/NW/0274), and written informed consent was obtained from all 
participants. The current analyses were conducted under approved 
UKB data application number 15110.
Phenotype definition
Questions from the UKB baseline assessment were used to develop 
two study groups: heavy drinkers (cases) and drinkers not reaching 
criteria for cases (controls). All participants who indicated they 
consumed alcohol were asked to quantify their intake per week or 
per month using standard drink sizes [e.g., “In an average WEEK, 
how many glasses of RED wine would you drink? (there are six 
glasses in an average bottle)”]; pictures accompanied these questions 
to provide visual representation of each measure. We then applied a 
standardized number of U.K. alcohol units to each drink to enable 
an estimated number of units per week to be calculated (see the 
Supplementary Materials for more detail). Sex-specific heavy drinking 
was then defined as >35 U/week for women and >50 U/week for 
men. Any cases with values >4 SDs above the gender-specific means 
were removed. Controls were individuals who were not current 
abstainers from alcohol (i.e., ≥1 U/week) but did not reach the 
sex-specific criteria for heavy drinking and were drinking at similar 
levels to 10 years previous.
Genotyping, imputation, QC, and GWAS
In July 2017, UKB released genetic information (directly typed and 
imputed genotypes) for the entire cohort (n = 487,406) to approved 
collaborators. Most (90%) of the participants were genotyped on 
the UKB Axiom Array, with the remaining 10% genotyped on the 
Affymetrix UK BiLEVE Axiom Array. There is >95% content overlap 
between arrays. Genotyping, QC, and imputation were performed 
centrally by UKB and has been previously described (43). Imputation 
was performed up to combined reference panels from the 1000 Genomes 
Project (Phase 3), UK10K, and Haplotype Reference Consortium (44). 
Analyses were restricted to a subset of white British individuals, defined 
on the basis of self-reported ethnicity and genetic data.
Using UKB data, univariate and multivariate logistic regressions 
were used to determine covariates to be included in the GWAS analysis. 
Variables only available for the entire cohort and implicated in pre-
vious research were considered, and any values >4 SDs from the 
mean were removed (n = 7649 participants removed due to missing 
data). Variables reaching P < 0.01 in separate univariate analysis 
were carried forward to a multivariate model, where the stepAIC 
function of the “MASS” R package was used to determine stepwise 
entry of variables into the model. Collinearity was determined using 
variance inflation factor, and variables were accordingly removed 
from the final model (Variance Inflation Factor >10). An a priori 
decision was made to include age and sex in all models. Our rationale 
for using this approach is twofold: first, to account for confounding 
factors that may bias effect estimates, and second, to improve power 
by reducing residual variance.
Genetic association analysis in autosomes was conducted using 
a linear mixed model in BOLT-LMM v2.3.1 (45), adjusted for age at 
recruitment, sex, genotyping array, and nongenetic covariates iden-
tified in the logistic regression model. The BOLT-LMM model in-
cludes a random effect derived from a genetic relationship matrix to 
account for population structure and relatedness. Potential P value 
inflation due to residual population structure and relatedness was 
checked using genomic control following filtering of variants based 
on imputation quality (INFO ≥0.4) and minor allele frequency of 
0.005. Distance-based clustering was used for defining loci, such that 
genome-wide significant SNPs were ranked from most significant to 
least significant, and SNPs were retained if they did not map ±500 kb 
of a more significant SNP. Variants reaching P < 5 × 10−6 and sur-
viving distance-based clustering (i.e., lead SNPs) in the UKB cohort 
were explored in the GERA cohort for the purposes of replication.
Replication cohort
The GERA cohort was used for replication. GERA is part of the Kaiser 
Permanente Research Program on Genes, Environment, and Health 
(RPGEH) and has been described in detail elsewhere (46). In short, 
the cohort comprises 110,266 adult men and women who are 
consented participants in the RPGEH, an unselected cohort of adult 
participants who are members of Kaiser Permanente Northern 
California, an integrated health care delivery system. All study 
procedures were approved by the Institutional Review Board of the 
Kaiser Foundation Research Institute.
For this replication analysis, 47,967 GERA participants of non- 
Hispanic white ethnicity who had alcohol consumption information 
were included. Alcoholic drinks consumed per week as a quantitative 
trait (drinks/week) was assessed on the basis of the RPGEH survey 
as previously described (12) and as part of the Supplementary 
Materials. Genotyping using Affymetrix Axiom arrays (Affymetrix, 
Santa Clara, CA, USA) (47, 48), imputation using the cosmopolitan 
1000 Genomes Project reference panel, and GWAS analysis were 
undertaken as detailed in the Supplementary Materials.
Meta-analysis
METAL was used to perform a fixed-effects meta-analysis between 
the UKB and GERA cohorts using Stouffer’s method to account for 
the effect sizes in discovery and replication being on different scales 
(49). An overall z-statistic and P value were calculated from a weighted 
sum of the individual statistics. Weights are proportional to the 
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square root of the number of individuals examined in each sample 
and selected such that the squared weights sum to 1.0.
A validated association was defined as follows: (i) reaching 
P < 5 × 10−6 in the discovery cohort, (ii) demonstrating nominal 
association with the same direction of effect in the replication cohort, 
and (iii) meeting genome-wide significance in the meta-analysis of 
both datasets sets.
Conditional analysis
Conditional analysis was performed on validated associations using 
Genome-wide Complex Trait Analysis (50) (http://cnsgenomics.
com/software/gcta/) and the GWAS outcomes from the UKB to 
identify independent signals in the same region as each lead SNP 
(±500 kb); one model was fitted per region. A set of 5000 randomly 
selected UKB white British participants was used to develop a refer-
ence set to approximate LD. A threshold of P < 1 × 10−5 was used to 
select index SNPs for independent signals in each region, where the 
conditional estimates were derived from fitting all independent SNPs 
jointly (i.e., joint model).
In silico analysis
Expression quantitative trait loci
The GTEx Portal (http://www.gtexportal.org) was used to assess 
whether the lead SNP at each locus was an eQTL for local genes 
across the range of available tissues (51). This approach uses gene 
expression information across various human tissue types and geno-
type data to build information on eQTLs using a ±1-Mb cis-window 
around the transcription start site. All tissue types with more than 
70 samples available within GTEx were evaluated in our analysis 
including the brain, heart, liver, skeletal muscle, and skin. Significant 
eQTLs were based on a false discovery rate (FDR < 0.05) correction. 
The LD between the top eQTL SNP for any eQTL signal and the 
GWAS SNP was assessed to explore whether the two signals colo-
calize with each other; an LD r2 > 0.8 in Europeans from the 1000 
Genomes was considered evidence of colocalization.
Genetic correlations
LD Hub v1.9.0 (http://ldsc.broadinstitute.org/ldhub/) was used to 
identify genetic correlations through LD score regression between 
the binary alcohol phenotype and other complex traits (52). This 
method uses individual SNP allele effect sizes from GWAS summary 
statistics and the average LD in a region to estimate bivariate genetic 
correlations. We tested for genetic overlap between alcohol consump-
tion from our GWAS and disease outcomes and related traits in 
European cohorts available in the LD Hub, except for UKB outcomes 
and metabolites due to the large number of potential comparisons. 
FDR < 0.05 was used to account for multiple comparisons.
Mendelian randomization
MR-Base v0.4.21 was used for performing two-sample MR to explore 
the causal relationship between alcohol consumption and other disease 
outcomes and related traits (53). Outcomes were selected from the 
NHGRI-EBI GWAS catalog and filtered for European ancestry–
only populations. All genome-wide significant SNPs were initially 
considered. Before MR analysis, the identified SNPs were explored 
for independence using estimated LD scores from the 1000 Genomes 
Project European sample, where r2 ≥ 0.001 among SNPs in a 10,000-kb 
region resulted in only the SNP with the lowest P value being retained. 
One hundred eleven outcomes were selected on the basis of being 
diseases of interest, metabolites influenced by alcohol and prominent 
in subsequent alcohol-related disease onset or progression (e.g., 
triglycerides), or other consequences of heavy alcohol consumption. 
Harmonization between exposure data and outcome data was under-
taken to ensure effects corresponded to the same allele. Causal 
estimates between exposure and outcomes were obtained using the 
two-sample MR IVW method with FDR for multiple comparisons. 
Sensitivity analyses to account for pleiotropy were performed using 
MR-Egger regression and weighted median approaches. The weighted 
median test has been suggested as an alternative to the MR-Egger 
when the instrumental variable contains a small number of SNPs.
PheWAS
Gene ATLAS (http://geneatlas.roslin.ed.ac.uk/) was used as a lookup 
for outcomes from PheWAS analysis performed on UKB traits (54). 
The database contains data from >450,000 white British individuals, 
>31 million variants, and 778 traits; only ICD-10 traits were considered 
(n = 496). This information was used to derive a phenome-wide 
significance threshold,  divided by the number of independent 
tests, i.e., 1.68 × 10−5 [0.05/(496*6)].
Pathway analysis
Reactome pathway knowledgebase (https://reactome.org/) was used 
to undertake pathway analysis (55). The Reactome Knowledgebase 
systematically links human proteins to their molecular functions, 
providing a resource that operates both as an archive of biologi-
cal processes and as a tool for discovering unexpected functional 
relationships. Loci identified through distance-based clustering 
at a relaxed threshold of P < 5 × 10−6 from the GWAS analysis 
were included. These loci were mapped to pathways, and a P value 
was calculated on the basis of the overlap between the query and 
the pathway expression; an FDR correction was applied by the 
software.
Assessment of function using model organisms
C. elegans is an excellent genetic model for investigating whole- 
animal effects of alcohol (56–58). Similar to humans, acute expo-
sure to intoxicating alcohol induces a dose-dependent reduction 
in coordinated movement of C. elegans both in solution (59) and 
on solid agar (60). Strains of C. elegans were selected on the ba-
sis of the outcomes from the present GWAS at the level of P < 
5 × 10−8 and having evidence of replication in GERA or being 
reported as genome-wide significant in other alcohol phenotype 
studies.
Phenotypic and RNA interference experiments were performed 
at 20°C in a temperature-controlled room on young adult her-
maphrodites selected from sparsely populated NGM (nematode 
growth media) plates. As we and others have previously demon-
strated (59, 60), exposure to 400 mM external ethanol reduces 
coordinated locomotion of wild-type (Bristol N2) animals by ~70%. 
An external concentration of 400 mM ethanol is equivalent to an 
internal concentration of ~20 to 70 mM, which is equivalent to a 
blood alcohol level of ~0.1 to 0.4% and is consistent with levels of 
intoxication experienced by humans. Locomotion rate was the outcome 
of interest and was quantified by thrashing in Dent’s solution [140 mM 
NaCl, 6 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 5 mM Hepes 
(pH 7.4) with bovine serum albumin at 0.1 mg/ml] as previous de-
scribed (59, 60). See the Supplementary Materials for full details.
All functional data are expressed as means ± SE. Thirty treated 
and untreated animals were analyzed and compared per strain per 
experiment. Statistical significance was assessed by one-way analysis 
of variance (ANOVA) with post hoc Bonferroni correction for mul-
tiple comparisons.
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